Abstract: The present invention relates to compounds able to inhibit ?-synuclein aggregation, their use in the treatment or prophylaxis of a synucleinopathy and to pharmaceutical compositions comprising said compounds.

Abstract: The present invention is applicable in the field of molecular dynamics, said invention consisting of computing methods for predicting the structure and function of biomolecules, and particularly of proteins, by means of simulating the protein folding process and the interaction process of proteins with other biomolecules in a solvent. More particularly, the invention relates to a method and a system for controlling simulation stability and for choosing the timestep used in the numerical integration of the equations of motion. The invention successfully reduces the molecular dynamics simulation time by means of optimizing the timestep choice through an adaptive control or allowing larger timesteps correcting the trajectories based on a power control.

Abstract: The present invention is applicable in the field of molecular dynamics, said invention consisting of computing methods for predicting the structure and function of biomolecules, and particularly of proteins, by means of simulating the protein folding process and the interaction process of proteins with other biomolecules in a solvent. More particularly, the invention relates to a method and a system for controlling simulation stability and for choosing the timestep used in the numerical integration of the equations of motion. The invention successfully reduces the molecular dynamics simulation time by means of optimizing the timestep choice through an adaptive control or allowing larger timesteps correcting the trajectories based on a power control.

Abstract: Compounds of the general formula (I) or salts thereof, for use as a pharmaceutical composition for treating infectious diseases, especially for treating diseases caused by Helicobacter are disclosed. R1 is an H atom, an X atom or a CXmH3-m radical wherein each X can be the same or different and is a halogen selected from F, Cl, Br or I, and m is an integer between 1 and 3; R2 is an NO2 group, a COOR? group or an SO3R? group; R? is a hydrogen (H) atom or a C1-C6 alkyl group; and n is an integer between 1 and 5.

Abstract: The invention relates to a compound of general formula (I) for use in a pharmaceutical composition for treating infectious diseases caused by Helicobacter pylori. R1 and R2 are O, S or N, and can be identical or different; R3 is O or S; R4 is H or a C1-C6 alkyl group; n represents a value between 0 and 3; and R5 is an NO2, COOR? or SO3R? radical, where R? is a H or a C1-C6 alkyl group.

Abstract: The present invention relates to the use of specific types of compounds acting as pharmacological chaperones having a stabilizing activity on the phenylalanine hydroxylase (PAH) enzyme for the prophylaxis and/or treatment of hyperphenylalaninemia (HPA) and phenylketonuria PKU) and diseases, disorders and conditions related thereto. Further, the present invention relates to pharmaceutical compositions containing the compounds according to the present invention as well as to methods of treatment of HPA, in particular, PKU and diseases, disorders and conditions related thereto.

Abstract: Use of the general formula compound (I), or any salt thereof, for preparation of a pharmaceutical compound for the treatment of infections illnesses, in particular for the treatment of Helicobacter. Y is NO2, COOH or SO3H; Z is O, N or S; X1 and X2 are halogen atoms which may be the same or different; and m and n take values from 0 to 3 and may be equal or different.

Abstract: Use of the general formula compound (I), or any salt thereof, for preparation of a pharmaceutical compound for the treatment of infections illnesses, in particular for the treatment of Helicobacter. Y is NO2, COOH or SO3H; Z is O, N or S; X1 and X2 are halogen atoms which may be the same or different; and m and n take values from 0 to 3 and may be equal or different.

Abstract: The present invention relates to the use of specific types of compounds acting as pharmacological chaperones having a stabilizing activity on the phenylalanine hydroxylase (PAH) enzyme for the prophylaxis and/or treatment of hyperphenylalaninemia (HPA) and phenylketonuria PKU) and diseases, disorders and conditions related thereto. Further, the present invention relates to pharmaceutical compositions containing the compounds according to the present invention as well as to methods of treatment of HPA, in particular, PKU and diseases, disorders and conditions related thereto.

Abstract: Compounds of the general formula (I) or salts thereof, for use as a pharmaceutical composition for treating infectious diseases, especially for treating diseases caused by Helicobacter are disclosed. R1 is an H atom, an X atom or a CXmH3-m radical wherein each X can be the same or different and is a halogen selected from F, Cl, Br or I, and m is an integer between 1 and 3; R2 is an NO2 group, a COOR? group or an SO3R? group; R? is a hydrogen (H) atom or a C1-C6 alkyl group; and n is an integer between 1 and 5.

Abstract: The invention relates to a compound of general formula (I) for use in a pharmaceutical composition for treating infectious diseases caused by Helicobacter pylori. R1 and R2 are O, S or N, and can be identical or different; R3 is O or S; R4 is H or a C1-C6 alkyl group; n represents a value between 0 and 3; and R5 is an NO2, COOR? or SO3R? radical, where R? is a H or a C1-C6 alkyl group.